Home
Products
- Transfected Stable Cell Lines
  Reliable | High-Performance | Wide Rage
  Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
  Transfected Stable Cell Lines
- Premade Virus Particles
  Ready-to-Use | High Titer | Versatile Applications
  Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
  Premade Virus Particles
- Virus-Like Particles (VLPs)
  Stable | Scalable | Customizable
  Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
  Virus-Like Particles (VLPs)
- Oligonucleotide Products
  Precise | High Yield | Tailored Solutions
  Accelerate your research with cost-effective LncRNA qPCR Array Technology.
  Oligonucleotide Products
- RNA Interference Products
  Targeted | Potent | High Specificity
  Human Druggable Genome siRNA Library enables efficient drug target screening.
  RNA Interference Products
  - shRNA Clones
  - siRNA Libraries
- Recombinant Drug Target Proteins
  Authentic | Versatile | Accelerated
  Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
  Recombinant Drug Target Proteins
- Clones
  Validated | Reliable | Comprehensive Collection
  Ready-to-use clones for streamlined research and development.
  Clones
- Kits
  Complete | Convenient | High Sensitivity
  Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
  Kits
- Enzymes
  Purified | Stable | Efficient
  Powerful Tn5 Transposase for DNA insertion and random library construction.
  Enzymes
  - Modified Enzyme
  - Restriction Enzyme
- Aptamers
  Highly Specific | Robust | Versatile
  Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
  Aptamers
- Adjuvants
  Enhancing | Synergistic | Effective
  Enhance immune responses with high-purity, potent CpG ODNs.
  Adjuvants
- Laboratory Equipment
  Innovative | Reliable | High-Precision
  Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
  Laboratory Equipment
Services
- Stable Cell Line Generation
  Reliable | Scalable | Customizable
  Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
  Stable Cell Line Generation
- Target-based Drug Discovery Service
  Innovative | Comprehensive | Efficient
  Target identification, validation, and screening for drug discovery and therapeutic development.
  Target-based Drug Discovery Service
- Custom Viral Service
  Versatile | High-Yield | Safe
  Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
  Custom Viral Service
- Custom Antibody Service
  Precise | Flexible | Efficient
  End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
  Custom Antibody Service
- Antibody-Drug Conjugation Service
  Integrated | Controlled | Translational
  Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
  Antibody-Drug Conjugation Service
- Protein Degrader Service
  Efficient | High-Precision | Advanced Therapeutics
  Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
  Protein Degrader Service
- Nucleotides Service
  Accurate | Flexible | High-Quality
  Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
  Nucleotides Service
- Custom RNA Service
  Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
  RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
  Custom RNA Service
- Custom Libraries Construction Service
  Comprehensive | High-throughput | Accurate
  Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
  Custom Libraries Construction Service
- Gene Editing Services
  Precise | Efficient | Targeted
  Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
  Gene Editing Services
- Microbe Genome Editing Service
  Precise | Scalable | Customizable
  Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
  Microbe Genome Editing Service
  - CRISPR Based Microbe Genome Editing Service
  - Recombineering Based Microbe Genome Editing Service
- Biosafety Testing Service
  Reliable | Comprehensive | Regulated
  Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
  Biosafety Testing Service
- Plant Genetic Modification Service
  Advanced | Sustainable | Tailored
  Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
  Plant Genetic Modification Service
- Plant-based Protein Production Service
  Efficient | Scalable | Customizable
  Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
  Plant-based Protein Production Service
  - Plant Cell Suspension-based Protein Production
  - Rice Endosperm-Specific Expression System
- Aptamer Discovery & SELEX Solutions
  Innovative | Fast | Cost-Effective
  Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
  Aptamer Discovery & SELEX Solutions
  - Aptamers Services
  - Technology Platforms
Applications
- Membrane Proteome Chip Antibody Off-Target Screening Service
  Membrane Proteome Chip Antibody Off‑Target Screening
  Native‑conformation | Quantitative | Cross‑reactivity free
  Membrane Proteome Chip Antibody Off-Target Screening Service
- CGT Biosafety Testing
  Comprehensive | Accurate | Regulatory-compliant
  Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
  CGT Biosafety Testing
- Pandemic Detection Solutions
  Rapid | Precise | Scalable
  Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
  Pandemic Detection Solutions
CDMO
- HEK293 Cell-Based Production Platform
- cGMP Cell Line Development
  Reliable | Scalable | Industry-leading
  Stable expression over 15 generations with rapid cell line development in just 3 months.
  Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
  cGMP Cell Line Development
- GMP mRNA Production
  Efficient | Scalable | Precise
  Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
  GMP mRNA Production
- GMP Plasmid Production
  High Quality | Scalable | Regulatory-compliant
  Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
  GMP Plasmid Production
- GMP Viral Vector Manufacturing
  Scalable | High Yield | Quality-driven
  Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
  GMP Viral Vector Manufacturing
AI
- AI-Driven Gene Editing and Therapy
  Innovative | Precision | Transformative
  AI-powered one-click design for customized CRISPR gene editing strategy development.
  AI-Driven Gene Editing and Therapy
- AI-Antibody Engineering Fusion
  Next-Generation | Targeted | Efficient
  AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
  AI-Antibody Engineering Fusion
- AI-Driven Enzyme Engineering
  Smart | Efficient | Tailored
  High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
  AI-Driven Enzyme Engineering
- AI-Enhanced Small Molecule Screening
  Predictive | Efficient | Insightful
  Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
  AI-Enhanced Small Molecule Screening
- AI-Driven Protein Degrader Drug Development
  Innovative | Targeted | Accelerated
  Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
  AI-Driven Protein Degrader Drug Development
Support
About Us

Inquiry

Pages

Products

Nipah Virus Research Solutions

Neutralization AssayRecombinant ProteinsmRNA-LNPsVLPsOverexpression Cell LinesAntibodiesMolecular Detection Kits

Overview

In January 2026, a new outbreak of Nipah virus (NiV) was reported in West Bengal, India, drawing significant international attention. The WHO subsequently reissued a public health alert, highlighting the virus's exceptionally high case fatality rate of 40%–75% and its potential pandemic risk. Compared with the Ebola virus, NiV is characterized by a more insidious onset, a longer and variable incubation period, and a zoonotic transmission cycle, making early detection and containment considerably more challenging. Although initial symptoms are often nonspecific, the disease can rapidly progress to severe encephalitis or acute respiratory failure within a short timeframe.

With no approved therapeutics or vaccines, NiV remains a high-risk pathogen in virology and immunology research. Leveraging expertise in recombinant proteins, nucleic acid delivery, virus-like particles (VLPs), and antibody engineering, Creative Biogene has developed a systematic and modular portfolio of Nipah virus research products to support multi-level scientific investigation, from fundamental mechanisms to translational applications.

Virological Characteristics and Genome Organization of Nipah Virus

Nipah virus belongs to the family Paramyxoviridae, genus Henipavirus, and is an enveloped, single-stranded negative-sense RNA virus. Viral particles exhibit pronounced pleomorphism, with diameters ranging from approximately 40 to 600 nm. The NiV genome is approximately 18.2 kb in length, substantially larger than that of most classical paramyxoviruses, a feature that underlies its complex transcriptional regulation and pathogenic potential.

The NiV genome encodes the following proteins in a 3′ to 5′ orientation:

N (nucleocapsid protein)
P (phosphoprotein)
M (matrix protein)
F (fusion protein)
G (glycoprotein)
L (RNA-dependent RNA polymerase)

Figure 1. Structure of Nipah virus. (Singh RK, et al., 2019)

The N, P, and L proteins form the viral replication and transcription complex and are essential for maintenance of the viral life cycle. Through RNA editing, the P gene also gives rise to multiple non-structural protein variants, including the V, W, and C proteins. These proteins effectively antagonize host STAT1/STAT2 signaling pathways and constitute a key molecular basis for NiV-mediated suppression of innate immune responses and immune evasion.

Viral Entry and Transmission Mechanisms

Nipah Virus Pseudovirus Neutralization Assay Service

Creative Biogene provides a standardized pseudovirus-based neutralization assay for functional evaluation of NiV entry inhibition. NiV G/F–pseudotyped viral particles carrying a reporter gene are pre-incubated with test samples (sera, plasma, monoclonal antibodies, or antibody fragments) and then applied to permissive target cells expressing ephrin-B2/B3. The reduction of reporter signal relative to virus-only controls determines neutralizing activity.

NiV G and F glycoproteins are co-expressed with a replication-defective, reporter-encoding viral backbone to generate pseudoviruses.

Neutralization Step

The mixture is added to ephrin-B2/B3–expressing target cells, and reporter signal is quantified to assess viral entry.

Data Analysis

Pseudovirus Production

Serially diluted antibodies or serum samples are pre-incubated with pseudovirus.

Cell Infection & Readout

Neutralization curves are generated, and inhibitory titers are calculated.

Service Highlights

Quantitative neutralization readout

ID₅₀ / IC₅₀ values derived from dose–response curves.

BSL-2 compatible platform

no use of live Nipah virus.

Broad sample compatibility

serum, plasma, monoclonal antibodies, and antibody fragments.

Creative Biogene's Nipah Virus Research Product Portfolio

Focusing on key molecular targets and experimental checkpoints throughout the NiV infection cycle, Creative Biogene has established a comprehensive product matrix encompassing recombinant antigens, mRNA-LNP formulations, virus-like particles, stable overexpression cell lines, functional antibodies, and molecular detection tools. This integrated portfolio provides standardized reagents that can be readily aligned with experimental designs at different stages of NiV research.

Recombinant Proteins

Creative Biogene offers multiple formats of NiV recombinant proteins, including full-length G protein and functional domains, F protein in distinct conformational states (pre-fusion and post-fusion), as well as the human ephrin-B2 receptor protein. These products enable receptor-binding analyses, immunogenicity assessments, and antibody screening under non-infectious conditions, providing reliable and reproducible materials for both fundamental and immunological studies of NiV.

Cat. No.	Product Name	Target	Tag / Format	Sequence Region	Price
NPP-001	Nipah Virus Glycoprotein G, His Tag	Glycoprotein G	His Tag	71–602	Inquiry
NPP-002	Nipah Virus Glycoprotein G (Head Domain), His Tag	Glycoprotein G	His Tag	178–602	Inquiry
NPP-003	Nipah Virus Pre-Fusion Fusion Glycoprotein, His Tag	Fusion Glycoprotein	His Tag	27–487	Inquiry
NPP-004	Nipah Virus Post-Fusion Fusion Glycoprotein, His Tag	Fusion Glycoprotein	His Tag	27–99 & 117–488	Inquiry
NPP-005	Human Ephrin-B2 Protein, His Tag	Ephrin-B2	His Tag	1–229	Inquiry

mRNA-LNP Products

These products provide standardized antigen delivery tools for nucleic acid vaccine-related research, facilitating exploratory studies under non-infectious conditions.

Cat. No.	Product Name	Target	Sequence Region	Price
NPR-001	Nipah Virus Glycoprotein G mRNA-LNP	Glycoprotein G	1–602	Inquiry
NPR-002	Nipah Virus Fusion Glycoprotein mRNA-LNP	Fusion Glycoprotein	1–546	Inquiry

Virus-Like Particles (VLPs)

Virus-like particles retain the native spatial organization of viral surface antigens while lacking viral genomic material, thereby combining enhanced biosafety with high structural and biological relevance.

Cat. No.	Product Name	Target	Sequence Region	Price
NPV-001	Nipah Virus Glycoprotein G Full-Length Protein (VLP)	Glycoprotein G	1–602	Inquiry
NPV-002	Nipah Virus Fusion Glycoprotein Full-Length Protein (VLP)	Fusion Glycoprotein	1–546	Inquiry

Overexpression Cell Lines

Creative Biogene provides stable HEK293 cell lines overexpressing NiV G or F proteins, suitable for studies of viral entry and membrane fusion mechanisms, antibody or receptor-blocking assays, and cell-based functional validation and imaging analyses.

Cat. No.	Product Name	Target	Sequence Region	Price
NPOE-001	HEK293 Cell Line Overexpressing Nipah Virus Glycoprotein G	Glycoprotein G	1–602	Inquiry
NPOE-002	HEK293 Cell Line Overexpressing Nipah Virus Fusion Glycoprotein	Fusion Glycoprotein	1–546	Inquiry

Antibodies

Creative Biogene offers a panel of research-grade antibodies targeting NiV G and F proteins, available in IgG, Fab, and scFv formats. These antibodies support epitope mapping, neutralization, and blocking assays, and the development and optimization of ELISA, immunofluorescence, and related analytical methods.

Cat. No.	Product Name	Target	Tag / Format	Price
NPA-001	Anti-Nipah Virus Glycoprotein G (HENV-26)	Glycoprotein G	Mouse IgG1	Inquiry
NPA-002	Anti-Nipah Virus Glycoprotein G (HENV-32)	Glycoprotein G	Mouse IgG1	Inquiry
NPA-003	Anti-Nipah Virus Glycoprotein G (nAH1.3)	Glycoprotein G	Fab	Inquiry
NPA-004	Anti-Nipah Virus Glycoprotein G (m102.3)	Glycoprotein G	Fab	Inquiry
NPA-005	Anti-Nipah Virus Glycoprotein G (m102.4)	Glycoprotein G	Fab	Inquiry
NPA-006	Anti-Nipah Virus Fusion Glycoprotein (5B3)	Fusion Glycoprotein	scFv	Inquiry
NPA-007	Anti-Nipah Virus Fusion Glycoprotein (Fab66)	Fusion Glycoprotein	Fab	Inquiry
NPA-008	Anti-Nipah Virus Fusion Glycoprotein (1F5)	Fusion Glycoprotein	Fab	Inquiry
NPA-009	Anti-Nipah Virus Fusion Glycoprotein (12B2)	Fusion Glycoprotein	Fab	Inquiry
NPA-010	Anti-Nipah Virus Fusion Glycoprotein (14F8)	Fusion Glycoprotein	Fab	Inquiry

Molecular Detection Kits

These kits can be applied in in vitro model validation, methodological development, and molecular-level analyses. When used in combination with recombinant antigens and antibodies, they support the construction of multi-layered and cross-validated NiV research workflows.

Cat. No.	Product Name	Price
NPD-001	Nipah Virus PCR Detection Kit	Inquiry
NPD-002	Nipah Virus qPCR Detection Kit	Inquiry

Value to Researchers

Creative Biogene's Nipah virus research products are not a simple collection of isolated reagents, but rather a combinable and scalable toolkit designed around the mechanisms of NiV infection and pathogenesis. This portfolio supports:

Dissection of viral entry and host–virus interaction mechanisms
Vaccine antigen design and comparative immunogenicity studies
Neutralizing antibody screening and functional validation
Early-stage exploration of novel antiviral strategies

As research on highly pathogenic viruses increasingly emphasizes biosafety, standardization, and reproducibility, Creative Biogene is committed to providing reliable, transparent, and literature-aligned solutions for Nipah virus research, facilitating the steady translation of fundamental discoveries toward applied outcomes.

References:

Singh RK, Dhama K, Chakraborty S, et al. Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review. Vet Q. 2019 Dec;39(1):26-55.
Al-Obaidi MMJ, Muthanna A, Desa MNM. Nipah Virus Neurotropism: Insights into Blood-Brain Barrier Disruption. J Integr Neurosci. 2024 Apr 29;23(5):90.
Mohabbat A, Bannazadeh Baghi H. Chronic Neuroplasticity Changes Following Neurotropic Viral Infection: Mechanisms and Implications. Cell Mol Neurobiol. 2025 Nov 4;45(1):94.

Quick Inquiry